Bausch Health Files 8-K: Director Changes & Executive Compensation Updates
Ticker: BHC · Form: 8-K · Filed: Jul 24, 2025 · CIK: 885590
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
Related Tickers: BHC
TL;DR
Bausch Health (BHC) filed an 8-K: new directors elected, exec comp updated. Governance changes underway.
AI Summary
On July 22, 2025, Bausch Health Companies Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election of new directors and updates to compensatory arrangements for certain officers, alongside financial statements and exhibits. This report signifies routine corporate governance updates and potential adjustments to executive incentives.
Why It Matters
This filing indicates potential shifts in the company's leadership and executive compensation structure, which could influence strategic direction and investor confidence.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance matters such as director elections and executive compensation, which typically carry a low immediate risk.
Key Players & Entities
- Bausch Health Companies Inc. (company) — Registrant
- July 22, 2025 (date) — Date of earliest event reported
- 0000885590 (company) — Central Index Key
- Valeant Pharmaceuticals International, Inc. (company) — Former company name
- BIOVAIL Corp (company) — Former company name
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors, but specific names and the exact number of new directors are not detailed in the provided excerpt.
What are the key updates regarding executive compensation?
The filing mentions updates to 'Compensatory Arrangements of Certain Officers,' but the specific details of these arrangements are not provided in this excerpt.
What is the significance of the 'Regulation FD Disclosure' item?
This item indicates that the company is making disclosures in compliance with Regulation Fair Disclosure, ensuring that material information is broadly disseminated.
When was Bausch Health Companies Inc. previously known as Valeant Pharmaceuticals International, Inc.?
The date of the name change from Valeant Pharmaceuticals International, Inc. to Bausch Health Companies Inc. was September 28, 2010.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 24, 2025 regarding Bausch Health Companies Inc. (BHC).